Trial Profile
A study evaluating skin rashes as a prognosis marker Afatinib efficacy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Mar 2018
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Mar 2018 New trial record
- 01 Mar 2018 Results (data cut off 30 September 2017) assessing safety and efficacy published in the Anticancer Research